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Abstract
Radiotherapy (RT) remains an effective treatment in patients with acromegaly refractory to medical and/or surgical
interventions, with durable tumor control and biochemical remission; however, there are still concerns about
delayed biochemical effect and potential late toxicity of radiation treatment, especially high rates of
hypopituitarism. Stereotactic radiotherapy has been developed as a more accurate technique of irradiation with
more precise tumour localization and consequently a reduction in the volume of normal tissue, particularly the
brain, irradiated to high radiation doses. Radiation can be delivered in a single fraction by stereotactic radiosurgery
(SRS) or as fractionated stereotactic radiotherapy (FSRT) in which smaller doses are delivered over 5-6 weeks in 25-
30 treatments. A review of the recent literature suggests that pituitary irradiation is an effective treatment for
acromegaly. Stereotactic techniques for GH-secreting pituitary tumors are discussed with the aim to define the
efficacy and potential adverse effects of each of these techniques.
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Introduction
Acromegaly is a disorder caused by a pituitary GH-
secreting adenoma and characterized by high circulating
levels of GH and IGF-I. It is associated with increased
morbidity and mortality rates, especially due to respira-
tory, cardiovascular disease, and malignant diseases [1].
Surgery, medical therapy, and radiotherapy (RT) are the
available treatments employed with the aim of normaliz-
ing GH and IGF-I hypersecretion, controlling pituitary
tumor mass effects, preventing recurrences, and improv-
ing morbidity. Transsphenoidal surgery is the procedure
of choice for the initial management of acromegaly,
leading to the remission of disease in 42-65% of patients
[2], and achieving a rapid improvement of metabolic
and cardiovascular abnormalities [3,4]. Medical therapy,
mainly with long-acting somatostatin analogs, permits a
normalization of GH/IGF-I hypersecretion in up to 70%
of cases with an apparently low incidence of side effects
[5]. RT is currently proposed to a subset of patients
with persistent active disease after surgery and/or during
medical therapy. In most of published studies conven-
tional RT achieves tumor growth control in 85-95% of
cases, dropping out GH/IGF-I levels to less than 5 ng/
ml in up to 80% of patients 10-15 years after RT [6].
Despite its efficacy, there are concerns about the neces-
sity and potential toxicity of RT and its use remains
matter of debate.
More recently, stereotactic radiation techniques have
been employed in patients with acromegaly with the aim
of treating less normal brain and of minimizing the
long-term consequences of RT while improving its
effectiveness [7]. Stereotactic radiotherapy can be given
as a single treatment (stereotactic radiosurgery-SRS)
using either cobalt-60 gamma radiation-emitting sources
(Gamma-Knife) or linear accelerator (LINAC), or as
fractionated stereotactic radiotherapy (FSRT). Although
stereotactic techniques have the clear advantage to offer
a more precise radiation delivery compared with con-
ventional RT, the question regarding their superiority
and efficacy in the management of patients with acro-
megaly remains to be demonstrated.
In this review, we present a critical analysis of the
more recent available literature in the management of
patients with acromegaly, in an attempt to define rea-
sonably objective and comparative information on the
safety and efficacy of the individual techniques.
Fractionated Radiotherapy
Modern RT even without the recourse to stereotactic
techniques has seen advances in all aspects of treatment
with better immobilization, imaging, planning and treat-
ment. Patients are typically immobilized in a custom
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Tumour localization, initially based on plain X-ray
visualization of the pituitary fossa, has improved with
the routine use of fused CT/MRI imaging. A margin of
3-10 mm beyond the visible extent of tumour is
included in the treatment planning to allow for patient
movement and set-up variation during the treatment.
Three-dimensional (3D) treatment planning provides
more accurate visualization of dose distribution as com-
pared with 2D planning, with the option of giving a
more homogeneous dose within the target and lower
dose to the organs at risk of radiation toxicity. More
precise delivery is achieved conforming the radiation
beams to the shape of tumor (conformal radiotherapy)
and increasing the number of beams. This results either
in reduction of volume of normal brain receiving high
dose of radiation or in a greater dose differential
between the target and normal brain tissue. The total
d o s eo f4 5 - 5 5G yi sa c h i e v e db yd a i l yd o s e so f1 . 8 - 2 . 0
Gy, with treatment lasting for 5-6 weeks.
Published series assessing the long term effectiveness
of conventional RT in patients with acromegaly report
tumor control and normalization of GH/IGF-I levels in
the region of 80-90% and 50-60% at 10 years, respec-
tively. The reported results are summarized in Table 1
[8-15]. Differing from earlier series based on basal GH
levels < 5-10 μg/liter to evaluate the biochemical remis-
sion of acromegaly after pituitary irradiation, more strin-
gent criteria for disease control are currently used [16].
In a series of 45 patients with active acromegaly trea-
ted with external beam RT at University of Rome La
Sapienza between 1982 and 1994 survival rates were
98%, 95%, and 93%, and local tumor control rates 95%
at 5, 10 and 15 years after treatment [14]. Biochemical
remission of disease as defined by GH levels below 1
ng/ml during an oral glucose tolerance test (OGTT) was
seen in 9% of patients at 2 years, 29% at 5 years, 52% at
10 years, and 77% at 15 years, respectively. IGF-I levels
were normal in 8% of patients 2 years after RT, and this
proportion increased to 23%, 42% and 61% after 5,10
and 15 years, respectively. In a large retrospective series
of 656 patients with acromegaly treated with conven-
tional pituitary irradiation in the United Kingdom the
proportion of patients who achieved a safe GH (< 2.5
ng/ml) was 22% at 2 years, 36% at 5 years, 60% at 10
years, and 74% at 15 years [15]. The biochemical remis-
sion rates were 35%, 49%, 73%, and 88% at 2, 5, 10, and
15 years for patients with a preirradiation GH levels less
than 10 ng/ml, compared with 11%, 27%, 51%, and 69%
for patients with preirradiation GH levels of 10-30 ng/
Table 1 Summary of results of recent series on fractionated radiotherapy for GH-secreting pituitary adenoma
Authors type
of
patients total
dose
follow-up tumor
control
biochemical remission late toxicity (%)
RT (Gy) median
(months)
% % visual hypopituitarism
Barkan et al., 1997 [8] CRT 38 46 80 NA 5 NA NA
Thalassinos et al., 1998
[9]
CRT 46 45-50 86 100 25 and 21 at 5 and 10
years
0 30 at 10 years
Barrande et al., 2000 [10] CRT 128 52 137 NA 35 and 53 at 5 and 10
years
3 50 at 10 years
Biermasz et al., 2000 [11] CRT 36 40 130 NA 40 and 61 at 5 and 10
years
0 29 and 54 at 5 and 10
years
Cozzi et al., 2001 [12] CRT 49 45 168 96 10 at 10 years 4 12
Epaminonda et al., 2001
[13]
CRT 67 40-75 120 NA 65 at 15 years 0 NA
Jenkins et al., 2006 [15] CRT 656 45 84 NA 36 and 64 at 5 and 10
years
0 58 at 10 years°
74 at 15 years
Minniti et al., 2005 [14] CRT 45 45 144 95 29 and 52 at 5 and 10
years
0 45 at 10 years
77 at 15 years
Milker-Zabel et al.,2004
[26]
FSRT 20 52.2 61 100 55 5 15
Colin et al., 2005 [27] FSRT 31* 50.4 80 99 20 and 50 at 5 and 10
years
03 7
Minniti et al., 2006 [28] FSRT 18* 45 39 98 50 at 5 years* 0 22
Roug et al., 2010 [29] FSRT 34 54 45 91 30 NA 29
CRT, conventional radiotherapy; FSRT, fractionated stereotactic radiotherapy.
*acromegalic patients included in series of FSRT for either secreting or non secreting pituitary tumors.
°hypogonadism 58%, hypothyroidism 27%, and hyposurrenalism 15%, respectively.
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patients at 2 years, 50% at 5 years, 63% at 10 years, and
56% at 15 years, respectively. Similar effects of pituitary
irradiation on GH and IGF-I levels have been reported
in some other retrospective series [10,11].
Analysis of rate of declining of individual GH levels
shows that plasma GH declines gradually to approxi-
mately 50% of the preirradiation value at 2 years, to 20%
at 5 years, and to 10% at 10 years, with a slower decline
of IGF-I concentration in the range of 50%-60% at 10
years [10,11,14]. This means that the interval to achieve
biochemical remission of acromegaly mainly depends on
GH/IGF-I preirradiation levels. Although RT was found
effective in the majority of treated patients in most ser-
ies, few studies reported a less favourable outcome
[8,9,12]. Differences in the length of follow-up, disease
activity, and biochemical testing procedures may, at
least in part, be responsible for these discrepancies.
The risk of late normal central nervous system toxicity
of external beam RT to doses less than 50 Gy at 2 Gy
per fraction is low, with a reported incidence of optic
neuropathy resulting in visual deficits of 1-5%, and a
risk of necrosis of normal brain structures of 0-2%.
Hypopituitarism represents the most commonly
reported late complication of RT, and its frequency
increases with longer follow-up, occurring in up to 60%
of irradiated patients 10 years after treatment (Table 1).
An increased incidence of cerebrovascular accidents
(CVA) and related mortality has been reported in
patients with acromegaly treated with conventional RT
[17,18]. Brada et al [17] found an increased mortality in
a series of 334 irradiated patients with a 1.6-fold excess
of CVA, and similar results have been reported by
others [18]. Since other possible risk factors include
GH/IGF-/excesses, hypopituitarism, and extensive sur-
gery, a direct link between RT and cerebrovascular
events remains to be proven. Conventional radiation of
pituitary tumors has been associated with the develop-
ment of secondary radiation-induced neoplasm, usually
a glioma or a meningioma [19,20]. In a cohort of 426
patients with pituitary adenomas [20] who received CRT
at the Royal Marsden Hospital (RMH) between 1962
and 1994, the cumulative risk of second brain tumours
was 2.0% (95% CI: 0.9-4.4%) at 10 years and 2.4% (95%
CI: 1.2-5.0%) at 20 years. The results are in consistent
with the reported cumulative risk of secondary glioma
after radiation of 2.7% at 15 years in a cohort of 305
patients with pituitary adenomas [19]. Developmental
problems leading to neurocognitive impairment, particu-
larly in children, is a recognized consequence of large
volume cranial irradiation [21]; however, there is little
evidence that fractionated irradiation for pituitary ade-
nomas may significantly alters cognitive function
[22-24].
FSRT is a refinement of high conformal RT with
further improvement in immobilization and delivery.
Patients undergoing FSRT are usually immobilized in a
highly precision frameless stereotactic mask fixation sys-
tem with a reported accuracy of 1-2 mm [25], so that it
is possible to administrate stereotactic irradiation in a
number of small doses/fractions. Thus, the principal aim
of FSRT is to deliver more localized irradiation as com-
pared with conventional RT, leading to a reduction of
t h ev o l u m eo fn o r m a lb r a i nt i s s u ei r r a d i a t e dt oh i g h
radiation doses, possibly minimizing the long-term con-
sequences of treatment.
Only few series report on the use of FSRT in patients
with GH-secreting pituitary adenomas showing tumor
control and biochemical remission rates of 90-100% and
8-55% at a variable follow-up of 30-60 months [26-29]
(Table 1). In a series of 18 patients with acromegaly trea-
ted with FSRT at Royal Marsden Hospital biochemical
remission was achieved in 35% after a median follow-up
of 39 months [28]. Actuarial normalization of GH/IGF-I
levels was 20% at 3 years and 50% at 5 years. Milker-
Zabel et al. [26] reported 5-year local and hormonal con-
trol rates of 100% and 80%, respectively, in 20 patients
with acromegaly. At a median follow-up of 30 months
Roug et al. [29] observed biochemical remission of dis-
ease, as defined by suppressed GH at OGTT and normal
IGF-I levels adjusted for age, in 30% of 34 patients with
active acromegaly, being 24%, 38% and 64% after 1,3 and
5 years, respectively. An additional 20% of patients
achieved normal GH and IGF-I levels with the use of
somatostatin analogs during the follow-up.
A low radiation-induced toxicity has been reported
after FSRT. Hypopituitarism is the most common com-
plication of treatment and has been reported in 15-37%
of patients at median follow-up ranging from 39 to 80
months, whereas the reported incidence of optic neuro-
pathy is 1-5%. The incidence of hypopituitarism is likely
to remain the major late effect of FSRT since it does
not result in a significant reduction of dose to the
hypothalamus and the residual normal pituitary tissue.
Although no cases of CVA and second tumors have
been reported after FSRT, the incidence of the former
increases with time, and secondary tumors usually occur
with many years delay. Although treating less normal
brain at high radiation doses may translate in a reduc-
tion of the development of such radiation induced com-
plications, large series and longer follow-ups need to
demonstrate these potential clinical advantages. Simi-
larly, the lack of formal cognitive function testing and
quality of life assessment in all published series does not
allow for definitive conclusion about the potential super-
iority of stereotactic techniques as compared with 3D
conformal RT, and this will need to be addressed in
future studies.
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sents an advanced form of 3D conformal RT with the
potential to achieve a much higher degree of target con-
formity while minimizing radiation exposure to sur-
rounding normal tissues, especially for tumors with
complex shapes and concave regions close to sensitive
structures. IMRT uses a series of multiple subfields cre-
ated by a multileaf collimator (MLC) which move under
computer control creating modulated fields. IMRT treat-
ment plans are generated using inverse planning system,
which uses computer optimization techniques to modu-
late intensities across the target volume and sensitive
normal structures, starting from a specified dose distri-
bution. IMRT may result in a more conformal and bet-
ter coverage than 3D conformal RT and therefore is
able to spare more normal brain. In 34 patients with
pituitary adenoma treated with IMRT at a median fol-
low-up of 42 months local control was 89% [30]. How-
ever, there are no reported clinical data on IMRT in
acromegaly, and currently, it is not possible to conclude
that IMRT confers any advantage over other techniques
with respect to either hormonal control or toxicity.
Particle radiation has been also applied successfully in
the treatment of pituitary adenomas. The physical prop-
erties of proton irradiation can offer superior conformal-
ity in dose distribution when compared to 3D conformal
RT and IMRT. Distribution of low and intermediate
d o s e st op o r t i o n so ft h eb r a i ni nc h i l d r e ni r r a d i a t e df o r
common brain tumors are significantly lower with pro-
tons when compared with photons [31], and the advan-
tage becomes more apparent for large volumes. Proton
therapy can be delivered as SRS or as FSRT with the
same immobilization systems and target accuracy of
photon techniques.
Petit JH et al [32] reported on 22 patients with persis-
tent acromegaly who were treated with single fraction
proton radiosurgery at Massachusetts General Hospital.
Using a median dose of 20 GyE biochemical remission
was achieved in 50% of patients, with a median time to
complete response of 30.5 months. One-third of patients
developed at least one new pituitary deficiency, requir-
ing medical therapy. In a small series of 11 acromegalic
patients treated with fractionated proton beam irradia-
tion at a median time of 83 months hormonal normali-
zation occurred in 45% of patients, with an actuarial
rate of 23% at 5 years [33]. Currently, no data suggest
the superiority of protons in the treatment of pituitary
tumors as compared with other radiation techniques.
Stereotactic radiosurgery (SRS)
SRS is given using either a multiple cobalt-60 (
60Co)
gamma radiation-emitting sources gamma knife (GK) or
a modified linear accelerator (LINAC). GK is the most
widely published radiosurgical methodology used to
treat pituitary adenomas. In its most common design, a
total of 201 sources of
60Co are arranged in a hemi-
sphere and focused with a collimator helmet on a single
or multiple fixed points (isocenters). CT localization and
computerized 3D planning are used to determine the
optimal number and distribution of isocenters, and this
can be aided by selective occlusion of collimator aper-
tures. During SRS, patients are usually immobilized in a
fixed frame with a positioning accuracy of < 1 mm.
Similar dose distribution can be obtained with a LINAC
using multiple noncoplanar arcs of rotation or multiple
noncoplanar fixed beams.
SRS has been extensively employed in the last two
decades in patients with residual pituitary tumors. At a
median follow-up ranging between 31 and 60 months
the reported tumor growth control following SRS in
patients with acromegaly is between 88 and 97% [34-48]
(Table 2). A variable reduction in tumor size has been
observed in 30-60% of patients after the treatment.
Biochemical remission of disease has been reported in
35-100% of patients with GH-secreting adenomas. The
variable rate of control disease may reflect the different
lengths of follow-up and criteria used to define the bio-
chemical control of disease, making difficult the evalua-
tion of the real efficacy of SRS. Nevertheless, when
stringent criteria of cure as defined by suppressed GH
levels during OGTT and normal age-corrected IGF-I
levels are considered, the 5-year actuarial biochemical
remission has been reported in 30-60% of patients fol-
lowing SRS, including patients who achieved normal
GH/IGF-I levels during medical treatment with soma-
tostatin analogs, and normalization of GH/IGF-I levels
continues throughout the follow-up period [36,40-42,44]
(Table 2).
Losa et al [44] in a retrospective analysis of 83
patients with acromegaly treated with GK SRS at Uni-
versity of Milan San Raffaele between 1994 and 2006
have reported actuarial biochemical remission rates of
30%, 52% and 85% at 3, 5 and 10 years, respectively.
Jagannathan et al [43] observed normalization of the
serum IGF-1 in 53% of 95 patients treated with GK SRS
and at least 18 months of follow-up. The mean time to
remission was 30 months; twelve patients achieved
endocrine remission within the first year of treatment,
28 within 2 years, and 34 within 3 years, respectively.
Jezkova et al [39] in a series of 96 patients reported hor-
monal remission rates of 45% at 3 years, 58% at 5 years,
and 57% at 8 years, respectively. The median time to
achieve GH suppression < 1 μg/l during an OGTT and
normal IGF-I was 66 months. Similar biochemical
remission rates in the range of 45-60% at 5 years have
been shown by others [41,42], although lower rates have
been reported in some series [34,36,40,48]. There are
only few studies on the efficacy of LINAC SRS for the
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general, they show comparable efficacy to GK SRS.
Several factors including preirradiation GH/IGF-I
levels, the use of somatostatin analogs, and radiosurgical
dose have been correlated with the endocrinological
outcome after SRS, although disagreement exists across
the published series.
High GH and/or IGF-I levels have been found inde-
pendently associated with worse SRS outcome in some
series [36,39,41,44], similar to that reported after con-
ventional RT [10,11,14,15]. Losa et al [44] reported a
median time for remission of 37 months for patients
with pre-treatment GH levels ≤ 7 μg/liter as compared
with 93 months for patients with GH levels > 7 μg/liter.
IGF-I levels ≤ 1.8 times the upper limit of normal
reached remission at a median time of 36 months as
compared with 90 months for patients with > 1.8 times
the upper limit of normal. Similarly, in a retrospective
analysis of 46 consecutive patients treated by SRS
between 1991 and 2004 at Mayo Clinic, preirradiation
IGF-I levels were independently correlated with bio-
chemical remission. The 3-year and 5 year biochemical
remission rates were 40% and 90% for patients with
IGF-I levels less than 2.25 times the upper limit of
normal, and 23% and 38% with IGF-I levels greater than
2.25 times the upper limit of normal, respectively.
Although no relationship between baseline hormonal
levels and remission of acromegaly has been reported in
few series [34,42], it seems reasonable that patients with
near-normal GH and IGF-I levels are more likely to
achieve hormonal remission than patients with markedly
abnormal pretreatment levels.
Whether the concomitant use of somatostatin analogs
at the time of SRS is a negative predictor of endocrine
normalization remains matter of debate. In Landolt at
al. [49] and Pollock et al. [41] series the use of suppres-
sive medications at the time of SRS negatively correlated
with biochemical remission of disease and increased the
time to hormonal normalization. In contrast, other
authors failed to show any detrimental effect of medical
treatment on outcome [34,36,44]. Although somatostatin
analogs withdrawal before SRS has gained an increase
acceptance in clinical practice, future prospective studies
are needed to elucidate the issue.
A variable dose of 18-32 Gy has been employed for
SRS in acromegaly. With some exceptions, marginal
dose to the tumor was not independently associated
with higher rate of remission or faster normalization of
Table 2 Summary of results of recent series on stereotactic radiosurgery for GH-secreting pituitary adenomas
Authors patients type of total
dose
follow-up tumor biochemical remission late toxicity (%)
SRS (Gy) median
(months)
control
(%)
(%) visual hypopituitarism
Attanasio et al., 2003 [34] 30 GK SRS 20 46 100 30 at 5 years 0 6.7
Jane et al., 2003 [35] 64 GK SRS 15 > 18 NA 36 0 28
Castinetti et al., 2005 [36] 82 GK SRS 26 49.5* NA 17 1.2 17
Gutt et al., 2005 [37] 44 GK SRS 23 22 100 48 NA NA
Kobayashi et al., 2005
[38]
67 GK SRS 18,9 63 100 17 11 15
Jezkova et al., 2006 [39] 96 GK SRS 32 53.7 100 44 at 5 years 0 27.1
Voges et al., 2006 [40] 64 LINAC
SRS
16,5 54.3 97 14 and 33 at 3 and 5
years
1.4 13 and 18 at 3 and 5
years
Petit et al., 2007 [32] 22 PSRS 20 GyE 75.6 100 59 0 38
Pollock et al., 2007 [41] 46 GK SRS 20 63 100 11 and 60 at 2 and 5
years
0 33 at 5 years
Vik-Mo et al., 2007 [42] 53 GK SRS 26.5 67 100 58 and 86 at 5 and 10
years
3.8 10 at 5 years
Jagannathan et al., 2008
[43]
95 GK SRS 22 57 98 53 4 34
Losa et al., 2008 [44] 83 GK SRS 21,5 69 97 52 and 85 at 5 and 10
years
0 10 at 10 years
Ronchi et al., 2009 [45] 35 GK SRS 20 114 100 46 at 10 years 0 50
Wan et al., 2009 [46] 103 GK SRS 21,4 67 95 37 0 6
Hayashi et al., 2010 [47] 25 GK SRS 25.2 36 100 40 0 0
Iwai et al., 2010 [48] 26 GK SRS 20 84 96 17 and 47 at 5 and 10
years
08
*mean follow-up; NA not assessed.
SRS, stereotactic radiosurgery; GKS, Gamma Knife radiosurgery.
PSRS; proton stereotactic radiosurgery.
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dose of about 20-25 Gy seems appropriate to achieve
either tumor control or hormonal normalization.
The reported overall rate of serious complications
after SRS is low (Table 2). The main complication is
hypopituitarism which is reported in 0-47% of patients,
with higher rates in those series with longer median fol-
low-up (Table 2). Pollock et al. [41] reported that one
third of 39 patients with acromegaly had a new pituitary
deficit following GK SRS, with an actuarial incidence of
new anterior pituitary deficits of 10% at 2 years and 33%
at 5 years, respectively. In a series of 95 patients with
acromegaly treated with GK SRS new endocrine defi-
ciencies were observed in 34% of patients. Incidence was
only 5% at 12 months after SRS, however increased to
more than 1/3 in patients with a follow-up longer than
49 months. A similar incidence of hypopituitarism at 5
years in the region of 20-40% has been observed in few
other series [39,42,45], suggesting that it will likely
increase significantly over time.
Other treatment-related complications occur rarely
after SRS. To minimize visual complications the dose
received by optic apparatus is usually restricted to less
than 8-10 Gy. In clinical practice this means that a dis-
tance between tumor margin and optic apparatus should
be at least of 2-3 mm to avoid the risk of visual dete-
rioration while delivering an effective dose of 16-20 Gy
to the tumor. Cavernous sinus is frequently irradiated at
high dose in patients with residual pituitary tumor,
although cranial neuropathies, brain radionecrosis, and
carotid artery stenosis have been reported infrequently
following SRS. Loeffler et al. [50] reported two cases of
secondary brain tumors after SRS for a pituitary ade-
noma. The risk to develop a new tumor after SRS
appears to be significantly less than that seen following
fractionated RT [20], however the relatively short length
of follow-up of most published series does not allow for
any definitive conclusion.
CyberKnife (Accuray, Sunnyvale, CA) is a relatively
new technological advancement in radiation therapy in
which a miniaturized low energy linear accelerator is
mounted on a robotic arm. The main advantage of
Cyberknife system is that it allows for frameless image-
guided radiation treatments achieving the same level of
targeting precision as frame-based SRS. It can be used
for multisession SRS (hypofractionated stereotactic
radiotherapy) in patients with tumors involving the
optic apparatus and who are not suitable for SRS [51].
Initial experiences with the application of CyberKnife
SRS or hypofractionated SRT in treating patients with
acromegaly are promising [52,53]. In a report of nine
patients with acromegaly treated with CyberKnife to
doses of 18-24 Gy in one to three fractions, biochemical
remission was observed in 4 patients at a mean follow
up of 25.4 months [53]. The efficacy of hypofractionated
treatment schedules which may offer a reduced risk of
radiation-related adverse effects as compared to single
fraction radiosurgery needs to be evaluated in future
studies.
A comparison of SRS with FSRT in terms of endocri-
nological outcome and toxicity is difficult to perform
since the choice of the different stereotactic treatment
modalities is based on different tumor characteristics:
patients with large tumors in close proximity of optic
apparatus are likely to be treated with FSRT than SRS.
In current practice SRS is usually offered to patients
with relatively small adenomas less than 3 cm in size
and more than 2-3 mm away from the optic apparatus
in order to avoid irradiation of the optic apparatus
beyond single doses of 8-10 Gy. In contrast, there is no
restriction to the size and the position of adenomas sui-
table for standard dose fractionated RT, since the treat-
ment is delivered within the radiation tolerance limits of
neural tissue, including the optic apparatus. Although
early series reported a faster decline of serum GH con-
centration after GK SRS as compared with FSRT
[49,54], the superiority of SRS in terms of time to hor-
monal normalization remains to be demonstrated.
Recent series have in fact showed that the rate of
decline of GH/IGF-I levels observed following SRS is in
the same region of that observed following fractionated
RT, suggesting that the variable time to hormonal nor-
malization is more dependent on preirradiation GH/
IGF-I levels than differences in radiation techniques
[34,36]. A lower incidence of hypopituitarism has been
suggested with the use of SRS as compared with FSRT,
although this is likely to reflect different patient selec-
tion. SRS is usually used to treat patients with smaller
tumors than those treated with FSRT. Prospective stu-
dies comparing SRS with fractionated stereotactic radio-
therapy in patients with pituitary adenomas similar in
size would be of value to help define the long-term effi-
cacy and toxicity of the techniques.
Conclusion
Radiation is highly effective in the management of
patients with persistent active acromegaly after surgery
and/or during medical therapy. Long-term data clearly
indicate that conventional RT is able to achieve bio-
chemical remission of disease in 50-60% of patients after
10 years, with an acceptable incidence of complications.
Stereotactic techniques (SRS and FSRT) offer a more
localized irradiation compared with conventional RT
and have the potential of reducing the risk of long term
radiation induced morbidity. Currently, SRS and FSRT
represent common treatment modalities of irradiation
for GH-secreting pituitary tumors, providing a compar-
able high rates of tumor control and endocrinological
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tion technique should be based on tumor characteristics.
In most centres SRS represent a convenient treatment
for patients with relatively small residual adenomas not
in close proximity of the optic chiasm, while FSRT is
usually reserved to patients with larger GH-secreting
tumors not amenable to SRS. Efficacy and toxicity of
hypofractionated treatment schedules need to be
explored in future studies.
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